A July 14, 2025 U.S. Food & Drug Administration (FDA) warning letter to a prominent wellness product and services company offers a blunt reminder that medical device requirements cannot be waived or overlooked merely because...more
Regulation of cannabidiol (CBD) was a hot topic on Day 1 of ACI’s Cosmetics & Personal Care Products conference on March 28, 2019. Attendees asked many questions about legitimate uses of and claims for CBD, but definite...more
4/1/2019
/ Cannabidiol (CBD) oil ,
Cannabis Products ,
Cosmetics ,
DEA ,
Dietary Supplements ,
Food and Drug Administration (FDA) ,
Health and Safety ,
Hemp ,
Labeling ,
Legislative Agendas ,
Marijuana ,
Marijuana Cultivation ,
Marijuana Related Businesses ,
Regulatory Oversight
From 2015 to 2016, FDA appeared to open the door to loosening the standards around intended use and off-label use, but recent rule-making and public comments suggest that FDA is becoming more sclerotic instead of flexible....more
2/20/2017
/ Citizen Petitions ,
First Amendment ,
Food and Drug Administration (FDA) ,
Healthcare Reform ,
Labeling ,
Medical Devices ,
Midnight Rules Relief ,
Off-Label Promotion ,
Off-Label Use ,
Pharmaceutical Industry ,
Qui Tam ,
Rulemaking Process ,
Transition Team ,
Trump Administration